We can’t show the full text here under this license. Use the link below to read it at the source.
Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
Effects of diabetes drugs on type 2 patients with kidney problems
AI simplified
Abstract
and systolic blood pressure significantly decreased in both treatment groups after 36 months.
- Both GLP-1 receptor agonist and SGLT-2 inhibitors were associated with significant reductions in HbA1c levels.
- Systolic blood pressure decreased significantly in both groups over the 36-month period.
- Estimated glomerular filtration rate showed a decrease, but this change was not statistically significant.
- decreased significantly in both groups, with a subsequent increase observed after 30 months in the SGLT-2 inhibitor group.
- Improvements in diastolic cardiac function, measured by specific cardiac indices, were noted only in the GLP-1 receptor agonist group at 36 months.
AI simplified
Key numbers
0.83%
Decrease in
Average reduction from baseline in both treatment groups after 36 months.
5.8 mmHg
Decrease in systolic blood pressure
Average reduction from baseline in both groups after 36 months.
9.7%
9.7% of patients
In Group G experienced a ≥30% decline in .